Unveiling the significance of Gremlin-1 as a novel biomarker for enhanced severity prediction in COVID-19 patients

Basit Öğe Kaydı
dc.authorid0000-0002-9536-8101
dc.contributor.authorCelik, Muhammet
dc.contributor.authorTekin, Erdal
dc.contributor.authorKocak, Mehmet Nuri
dc.contributor.authorUzuncakmak, Sevgi Karabulut
dc.contributor.authorBayraktar, Mustafa
dc.date.accessioned2026-02-28T12:17:58Z
dc.date.available2026-02-28T12:17:58Z
dc.date.issued2024
dc.departmentBayburt Üniversitesi
dc.description.abstractGremlin-1 is associated with lung disease and plays a role in the initiation and progression of pulmonary fibrosis. This suggests that Gremlin-1 may be associated with lung involvement in COVID-19 and poor clinical outcomes and warrants further investigation. This prospective, cross-sectional, single-blind study was the first to investigate Gremlin-1 levels in COVID-19 patients and whether Gremlin-1 levels could be used to predict and guide clinical follow-up in outpatients and inpatients. In this context, serum Gremlin-1 levels were measured and compared in 2 groups of patients who were diagnosed as positive for COVID-19 by RT-PCR and were followed up as outpatients (n = 28) or required hospitalization (n = 30). The median Gremlin-1 values were statistically significantly different between outpatients and intensive care unit patients (0.367 ng/mL [IQR = 0.377], 1.858 ng/mL [IQR = 2.245], respectively) (P < .0001). The area under the ROC curve value to determine the discriminative power of Gremlin-1 was found to be 0.772 (95% CI: 0.672-0.871; P < .0001), and the cutoff value of Gremlin-1 to discriminate between outpatients and hospitalized patients was found to be 1.242 ng/mL with 66.7% sensitivity and 67.2% specificity. Serum Gremlin-1 level is an important biomarker that can be used as a clinical decision-making tool for COVID-19 positive patients.
dc.identifier.doi10.1097/MD.0000000000040001
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue41
dc.identifier.pmid39465816
dc.identifier.scopus2-s2.0-85207328760
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000040001
dc.identifier.urihttps://hdl.handle.net/20.500.12403/6052
dc.identifier.volume103
dc.identifier.wosWOS:001338585900083
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofMedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260218
dc.subjectCOVID-19
dc.subjectdecision-making
dc.subjectGremlin-1
dc.subjecthospitalization
dc.subjectoutpatient
dc.subjectprediction
dc.titleUnveiling the significance of Gremlin-1 as a novel biomarker for enhanced severity prediction in COVID-19 patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu